Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery.
about
Effect of grapefruit juice on the disposition of omeprazoleA comparative evaluation of models to predict human intestinal metabolism from nonclinical data.Measurement of multiple drug resistance transporter activity in putative cancer stem/progenitor cells.Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.PharmGKB summary: cyclosporine and tacrolimus pathwaysReview: therapeutic drug monitoring in pediatrics.Sucralose, a synthetic organochlorine sweetener: overview of biological issuesA mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals.Remote communication through solute carriers and ATP binding cassette drug transporter pathways: an update on the remote sensing and signaling hypothesis.Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome.Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypesNanosuspensions: a promising drug delivery strategy.Practical aspects of transporter model systems: a case study involving SQV.Functional interaction of intestinal CYP3A4 and P-glycoprotein.In silico Analysis for Predicting Fatty Acids of Black Cumin Oil as Inhibitors of P-GlycoproteinPharmacokinetic principles of immunosuppressive drugs.A cost-effective system for differentiation of intestinal epithelium from human induced pluripotent stem cellsApplication of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.Basolateral and canalicular transport of xenobiotics in the hepatocyte: A review.Engineering strategies to enhance nanoparticle-mediated oral delivery.OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.The role of transporters in the pharmacokinetics of orally administered drugs.Altered functions and expressions of drug transporters in liver, kidney and intestine in disorders of local and remote organs: possible role of oxidative stress in the pathogenesis.Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant.Biomagnetic methods: technologies applied to pharmaceutical research.Gender differences in antidepressant drug response.The pharmacology of novel oral anticoagulants.Pharmacokinetic drug interactions involving Ginkgo biloba.Loss of orally administered drugs in GI tract.Immunosuppressive drug therapy--biopharmaceutical challenges and remedies.CYP3A4 and MDR1 alleles in a Portuguese population.CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease.In vitro experimental system for evaluating inhibitory effect of investigational drugs on P-glycoprotein-mediated transcellular transport of tacrolimus (FK506).Effects of berberine on pharmacokinetics of midazolam and rhodamine 123 in rats in vivoFrom preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example.Rifampin-sirolimus-voriconazole interaction in a hematopoietic cell transplant recipient.The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profile in non-cannulated mice.Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin.
P2860
Q24564982-6E236B98-784C-4A6D-AB97-546FC06087B9Q31159063-C141ACE9-C650-4A3A-8545-3A83368EBC58Q33479192-0601D0B9-A21C-468D-8779-8B43E16B1A25Q33807628-93C6809E-A6FD-4ABB-803D-8B7ACF8F3AE9Q33989902-6C4CA799-8DB3-4195-898C-F3A13E4F0566Q34503248-834F917E-D05D-4DDA-ABB1-39B514D92E19Q34657381-0FEEA626-CA8A-4AAA-8E67-CE9F2EC6089DQ34665881-C6D81BC6-40A4-4D97-812B-659F4E4F1B83Q34865706-93A0A479-DE2B-4889-8038-E90CF1A18175Q35547031-9C4D4939-AB69-4630-ABA9-61FD3137E3F8Q35826139-5FE1FC61-9B84-4944-BF4B-CFC5822A971BQ35826447-3202D2DC-06F8-475F-A1BD-052CDA504ACDQ35828049-0A767D1B-68E8-4A26-A015-80BA20AD60DFQ35952691-7F02A47B-A830-4A69-9F01-8865B17D1402Q35970006-4043BDBE-4631-4D30-AEE1-E3EAD1F989CDQ36006086-AA01DBFB-5EF4-4F9C-AEAC-A4D2E427A900Q36329502-4CD072B7-3266-4707-9D77-A82378ABBDDEQ36935249-BC3DE41E-4AB7-4B76-8854-DD2356CE648FQ37323581-5D8411A4-380A-44CD-8FA6-F14B3EE9CE42Q37328673-EF466AEB-360F-4DBE-A529-101EF52791CEQ37489569-F20C4543-17A3-4B9A-BB6B-60D5816CC03DQ37537018-CD5438BC-65F5-4EF8-BFC2-B2EEB577CB50Q37556541-0BBF66C3-3B15-4FCB-8729-BD2DAFAF6A88Q37772515-5F733F3F-1FD6-4E48-B798-3341A60685B2Q37800414-F11CBE5A-9C44-448B-B86F-461F8007A381Q37806757-B76A79CB-65D5-4F87-B5FB-BF530BF91FA1Q38122099-F3363D46-706D-4BF4-89E6-6EF201331F29Q38122439-D93816F2-76CC-4BB9-B6C1-2CF8C5DABDF9Q38130231-C493DC7B-C4FB-4F69-B07B-CC9B4C75572CQ38340831-07D70972-437C-457A-919B-B91511EE19F7Q38348695-372EF4E4-7473-4A79-9F4D-4588D8577B76Q38903289-95504126-1C43-4569-9837-E0E905B110BAQ38995566-F29BD5E0-76FF-49EE-9F3C-0400AE2E22F5Q39636386-7DF06E53-96BA-4D2F-88B5-595D9C758DBDQ39645850-5119A5F7-8571-44F5-AA84-E780A87117FCQ40834681-C424CD64-41DC-4D59-AFC0-AE67F19277BBQ41987156-4D9B6954-D28F-4540-8D9A-9AC1B60979FBQ43120631-C3C83A6E-9C1F-45D5-B6A3-4E88CF9F610EQ43257599-E4FFAC99-74E7-4DEF-991A-CF2464BD9518Q43865009-5E560276-9B25-44F1-8FFE-434BD486FBF5
P2860
Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery.
@en
type
label
Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery.
@en
prefLabel
Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery.
@en
P2093
P1476
Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery.
@en
P2093
P356
10.1016/S0168-3659(99)00034-6
P407
P577
1999-11-01T00:00:00Z